Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Scripps Research Institute and Aileron Therapeutics have entered into an agreement, which provides Aileron exclusive worldwide rights to utilise Scripps Research’s Click chemistry for therapeutics and non-exclusive worldwide rights for diagnostics with Aileron’s stabilized peptide and protein technology platforms.
Subscribe to our email newsletter
Aileron’s Stapled Peptide technology platform ‘locks’ peptides into their biologically active shape by the formation of one or more stabilising macrocycles, mimicking the structures found in nature.
Aileron said Stapled Peptide technology enables the expansion of the number of ‘druggable’ therapeutic targets by providing an opportunity to address the thousands of intracellular protein-protein interactions.
Click chemistry is designed to generate substances by joining small reactive molecular building blocks together selectively and covalently to facilitate a spontaneous and irreversible binding reaction.
The approach may effectively accelerate the drug discovery process by utilising a few practical and reliable reactions, and by making each reaction in a multistep synthesis fast, efficient and predictable.
Aileron chief scientific officer Tomi Sawyer said this agreement with Scripps Research further expands the arsenal to create novel therapeutics, including protein and non-helical peptide therapeutics.